Global Trial of Trontinemab Aims to Prevent Alzheimer's Disease Before Symptoms Appear
In recent years, significant advancements have been made in the search for treatments for Alzheimer’s disease. Notably, a trial in 2022 for the drug lecanemab demonstrated that it could slow the progression of Alzheimer’s, while another drug, donanemab, also showed encouraging results. Building on this momentum, researchers at the NHS are set to initiate a new global trial known as the PrevenTRON study, which will investigate the effects of an experimental drug called trontinemab. This trial is particularly focused on individuals who do not exhibit memory loss or other symptoms of Alzheimer’s, with the goal of assessing whether the drug can delay or even prevent the disease from progressing to dementia.
As part of the study, healthy participants aged between 55 and 80 from various countries will undergo blood tests to measure levels of p-tau217, a biomarker that has been shown to predict cognitive decline and the potential development of Alzheimer’s. Previous research indicates that blood tests for p-tau217 can identify Alzheimer’s disease with up to 95% accuracy, and it is estimated that approximately 78% of individuals with this biomarker may develop cognitive impairment within a decade.
Currently, Phase 3 of the trial is underway, involving around 1,600 participants from 18 countries who do not show symptoms of dementia but have elevated p-tau217 levels. The final results of the trial are not expected until at least 2028, when the current studies are projected to conclude.
Trontinemab, developed by the Swiss pharmaceutical company Roche, is designed to target amyloid plaques—harmful proteins that accumulate in the brain and damage brain cells over time. In Phase 2 of the trial, which included 100 individuals with early-stage Alzheimer’s, trontinemab successfully cleared amyloid plaques in 90% of participants within 28 weeks, suggesting its potential as a preventative treatment for those without symptoms.
Professor Ramin Nilforooshan, the chief investigator for the PrevenTRON trial, emphasized the shift in focus of research, stating, "For decades, research has concentrated on treating Alzheimer’s disease after symptoms appear. PrevenTRON addresses a different question: whether we can act earlier, before symptoms begin." This innovative approach could pave the way for new strategies in combating Alzheimer’s disease and improving the quality of life for millions at risk.




